MCID: SCN001
MIFTS: 50

Secondary Hyperparathyroidism of Renal Origin

Categories: Endocrine diseases, Nephrological diseases

Aliases & Classifications for Secondary Hyperparathyroidism of Renal Origin

MalaCards integrated aliases for Secondary Hyperparathyroidism of Renal Origin:

Name: Secondary Hyperparathyroidism of Renal Origin 12
Secondary Hyperparathyroidism 12 37 15
Hyperparathyroidism, Secondary 44 73
Hyperparathyroidism Due to Renal Insufficiency 12
Hyperparathyroidism Secondary 55

Classifications:



External Ids:

Disease Ontology 12 DOID:12465 DOID:12466
ICD10 33 N25.81 E21.1
ICD9CM 35 588.81
MeSH 44 D006962
NCIt 50 C113335
KEGG 37 H01669

Summaries for Secondary Hyperparathyroidism of Renal Origin

MalaCards based summary : Secondary Hyperparathyroidism of Renal Origin, also known as secondary hyperparathyroidism, is related to hyperparathyroidism and non-renal secondary hyperparathyroidism. An important gene associated with Secondary Hyperparathyroidism of Renal Origin is PTH (Parathyroid Hormone), and among its related pathways/superpathways are Ca, cAMP and Lipid Signaling and Parathyroid hormone synthesis, secretion and action. The drugs Benzocaine and Angiotensin II have been mentioned in the context of this disorder. Affiliated tissues include kidney, bone and endothelial, and related phenotypes are hematopoietic system and endocrine/exocrine gland

Related Diseases for Secondary Hyperparathyroidism of Renal Origin

Diseases related to Secondary Hyperparathyroidism of Renal Origin via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 86)
# Related Disease Score Top Affiliating Genes
1 hyperparathyroidism 23.9 ACP5 BGLAP CALCA CASR CYP27B1 EPO
2 non-renal secondary hyperparathyroidism 12.1
3 hypocalciuric hypercalcemia, familial, type iii 10.7 CASR PTH
4 hypoparathyroidism, familial isolated 10.7 CASR PTH
5 hypocalciuric hypercalcemia, familial, type ii 10.7 CASR PTH
6 oncogenic osteomalacia 10.7 FGF23 PTH
7 hypercalciuria, absorptive, 2 10.7 CASR VDR
8 familial hypocalciuric hypercalcemia 10.7 CASR PTH
9 axial osteomalacia 10.7 BGLAP PTH
10 extraskeletal chondroma 10.7 BGLAP PTH
11 pulmonary alveolar microlithiasis 10.6 FGF23 PTH
12 spondylosis 10.6 PTH VDR
13 xanthinuria, type i 10.5 CASR VDR
14 pseudohypoparathyroidism, type ib 10.5 BGLAP PTH
15 vitamin d-dependent rickets, type 2a 10.4 CYP27B1 VDR
16 nephrolithiasis, calcium oxalate 10.4 CASR VDR
17 sialolithiasis 10.3 ALB CASR
18 impaired renal function disease 10.3 BGLAP FGF23 PTH
19 idiopathic hypercalciuria 10.3 BGLAP CASR VDR
20 chondrocalcinosis 10.3 CASR TNFRSF11B
21 hypophosphatemia 10.3 BGLAP FGF23 PTH
22 multicentric carpotarsal osteolysis syndrome 10.3 ACP5 TNFRSF11B
23 camurati-engelmann disease 10.3 ACP5 BGLAP
24 pseudohypoparathyroidism 10.2 BGLAP PTH
25 periapical periodontitis 10.2 ACP5 TNFRSF11B
26 osteoporosis, juvenile 10.2 BGLAP CALCA
27 tooth resorption 10.2 ACP5 TNFRSF11B
28 nontoxic goiter 10.2 BGLAP CALCA
29 cloacogenic carcinoma 10.2 CALCA PTH
30 paget disease of bone 5, juvenile-onset 10.2 CALCA TNFRSF11B
31 uremic neuropathy 10.1 EPO PTH
32 autonomic nervous system disease 10.1 ALB CALCA
33 hypophosphatemic rickets with hypercalciuria, hereditary 10.1 CYP27B1 FGF23 PTH
34 mccune-albright syndrome 10.1 BGLAP FGF23
35 hypophosphatemic rickets, x-linked recessive 10.1 CYP27B1 FGF23 VDR
36 parathyroid carcinoma 10.0 CALCA CASR PTH
37 hyperphosphatemia 10.0 CASR FGF23 PTH VDR
38 hypocalcemia, autosomal dominant 1 10.0 CALCA CASR VDR
39 bone giant cell tumor 10.0 ACP5 CALCA
40 metaphyseal chondrodysplasia, jansen type 10.0 CALCA FGF23 PTH
41 multiple endocrine neoplasia, type iia 10.0 CALCA PTH
42 hypophosphatasia, adult 10.0 BGLAP CALCA PTH
43 splenic disease 10.0 ALB EPO
44 hypoparathyroidism 9.9 BGLAP CASR FGF23 PTH
45 root resorption 9.9 CALCA TNFRSF11B
46 fetal erythroblastosis 9.9 ALB EPO
47 diabetes mellitus, insulin-dependent 9.9 ALB BGLAP VDR
48 pure red-cell aplasia 9.9 ALB EPO
49 fibrogenesis imperfecta ossium 9.9 CALCA PTH TNFRSF11B
50 fibrous dysplasia 9.9 BGLAP CALCA FGF23

Graphical network of the top 20 diseases related to Secondary Hyperparathyroidism of Renal Origin:



Diseases related to Secondary Hyperparathyroidism of Renal Origin

Symptoms & Phenotypes for Secondary Hyperparathyroidism of Renal Origin

MGI Mouse Phenotypes related to Secondary Hyperparathyroidism of Renal Origin:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.87 PTH TNFRSF11B CASR VDR CYP27B1 EPO
2 endocrine/exocrine gland MP:0005379 9.85 PTH ALB CASR VDR CYP27B1 FGF23
3 immune system MP:0005387 9.8 FGF23 PTH TNFRSF11B CASR VDR CYP27B1
4 limbs/digits/tail MP:0005371 9.63 PTH TNFRSF11B VDR CYP27B1 EPO FGF23
5 renal/urinary system MP:0005367 9.35 ALB CASR VDR CYP27B1 FGF23
6 skeleton MP:0005390 9.17 PTH TNFRSF11B CASR VDR CYP27B1 EPO

Drugs & Therapeutics for Secondary Hyperparathyroidism of Renal Origin

Drugs for Secondary Hyperparathyroidism of Renal Origin (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 100)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
2
Angiotensin II Approved, Investigational Phase 4,Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
3
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
4
Racepinephrine Approved Phase 4 329-65-7 838
5
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
6
Sevelamer Approved Phase 4,Phase 3,Phase 2,Not Applicable 52757-95-6
7
Darbepoetin alfa Approved, Investigational Phase 4 11096-26-7, 209810-58-2
8
Ethanol Approved Phase 4 64-17-5 702
9
Calcium Carbonate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 471-34-1
10
Alendronate Approved Phase 4,Phase 2 121268-17-5, 66376-36-1 2088
11
Iron Approved Phase 4 7439-89-6 23925
12
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-14-6 5280793
13 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable
14
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1406-16-2
15
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 67-97-0 6221 5280795
16
Calcitriol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 32222-06-3 134070 5280453
17
Alfacalcidol Approved, Nutraceutical Phase 4,Not Applicable 41294-56-8 5282181
18
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 11103-57-4, 68-26-8 445354
19
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
20
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
21
Nicotinamide Approved, Investigational, Nutraceutical Phase 4 98-92-0 936
22 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Calcimimetic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
24 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Cinacalcet Hydrochloride Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
26 Ergocalciferols Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
28 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
29 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
30 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Vitamins Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
33 Angiotensin II Type 1 Receptor Blockers Phase 4,Phase 2
34 Angiotensin Receptor Antagonists Phase 4,Phase 2
35 Angiotensinogen Phase 4,Phase 2
36 Antihypertensive Agents Phase 4,Phase 2,Not Applicable
37 Epinephryl borate Phase 4
38 1 alpha-hydroxyergocalciferol Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Vasoconstrictor Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
41 Hydroxycholecalciferols Phase 4,Phase 3,Not Applicable
42 Calcifediol Phase 4,Phase 3,Not Applicable 19356-17-3
43 Epoetin alfa Phase 4 113427-24-0
44 Hematinics Phase 4
45 Antioxidants Phase 4
46 Butylated Hydroxytoluene Phase 4
47 Protective Agents Phase 4,Phase 3,Phase 2,Not Applicable
48 Antacids Phase 4,Phase 3,Phase 2,Not Applicable
49 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2,Not Applicable
50 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 198)
# Name Status NCT ID Phase Drugs
1 Cinacalcet in Management of Secondary Hyperparathyroidism in Haemodialysis Patients Unknown status NCT02338934 Phase 4 Combination Cinacalcet with Vitamin D analogue
2 Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity Unknown status NCT00288873 Phase 4 Ergocalciferol;Cholecalciferol
3 Physiologic Interactions Between the Adrenal- and the Parathyroid Glands Unknown status NCT02572960 Phase 4 Valsartan;Placebo Valsartan
4 How Bone is Made in Children Receiving Dialysis Unknown status NCT01799317 Phase 4 Vitamin D2
5 Anti-proteinuric Effect of Calcitriol in Non-diabetic Kidney Disease Patients Unknown status NCT01512862 Phase 4 Calcitriol;Placebo
6 Initial Dosing of Paricalcitol in Secondary Hyperparathyroidism Completed NCT00307840 Phase 4 paricalcitol
7 Parathyroidectomy vs Cinacalcet in the Treatment of Secondary Hyperparathyroidism Post Renal Transplantation Completed NCT01178450 Phase 4 Cinacalcet
8 Efficacy and Safety of Alfacalcidol Compared to Calcitriol for Treatment of Secondary Hyperparathyroidism Completed NCT01115543 Phase 4 alfacalcidol and calcitriol
9 ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism Completed NCT00135304 Phase 4 Sensipar®;Vitamin D
10 Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT) Completed NCT00823303 Phase 4 Paricalcitol;Calcitriol
11 Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis Completed NCT00537979 Phase 4 Paricalcitol injection;Paricalcitol capsules
12 Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation. Completed NCT01939977 Phase 4 Paricalcitol;Calcifediol
13 START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Completed NCT00132431 Phase 4 Sensipar
14 Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism Completed NCT00123461 Phase 4 Hectorol (doxercalciferol capsules), 0.5mcg
15 Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyperparathyroidism (SHPT) Among Subjects Undergoing Hemodialysis Completed NCT01181531 Phase 4 Traditional Vitamin D Therapy;Cinacalcet
16 Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose Completed NCT00891813 Phase 4 Zemplar (paricalcitol)
17 20070360 Incident Dialysis Completed NCT00803712 Phase 4 Cinacalcet;Vitamin D
18 Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH Level Completed NCT01101113 Phase 4 cinacalcet;control
19 A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection Completed NCT00463021 Phase 4 Hectorol (doxercalciferol capsules);Zemplar (paricalcitol injection)
20 Cincalcet and Vascular Arterial Stiffness Among Peritoneal Dialysis Patients With Secondary Hyperparathyroidism Completed NCT01143987 Phase 4 Cinacalcet
21 A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis Completed NCT00418600 Phase 4 Hectorol® (doxercalciferol capsules);doxercalciferol capsules, Hectorol®;doxercalciferol capsules, Hectorol® capsules
22 Vitamin D Deficiency in Chronic Kidney Disease (CKD) Patients Completed NCT00958451 Phase 4 Paricalcitol;Ergocalciferol
23 Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium Completed NCT00073710 Phase 4 Zemplar;Calcijex
24 Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D Completed NCT00977080 Phase 4 Paricalcitol;Cinacalcet
25 Treatment Adhesion in Dialysis Patients Treated With Cinacalcet Completed NCT01573520 Phase 4
26 A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With End Stage Renal Disease (ESRD) Completed NCT00431496 Phase 4 Cinacalcet
27 A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients Completed NCT01506947 Phase 4 Paricalcitol;Darbepoetin alfa
28 A Phase 4 Pharmacokinetic Study of Hectorol Injection and Zemplar Injection in CKD Subjects on Hemodialysis Completed NCT00454350 Phase 4 Hectorol (doxercalciferol injection);Zemplar (Paricalcitol injection)
29 Trial to Optimize Mineral Outcomes in Dialysis Patients Completed NCT01100723 Phase 4
30 Vitamin D and Coronary Calcification Study Completed NCT00752102 Phase 4 Calcitriol (Rocaltrol®);Paricalcitol
31 A Research Study for Patients With End-Stage Renal Disease (ESRD) Completed NCT00110890 Phase 4 cinacalcet
32 Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis Completed NCT00053547 Phase 4 paricalcitol injection
33 Paricalcitol Effect on Anemia in CKD Completed NCT01768351 Phase 4 Paricalcitol;Calcitriol
34 A Study of Zemplar® Injection and Hectorol® Injection on Intestinal Absorption of Calcium in Chronic Kidney Disease Completed NCT00257920 Phase 4 Zemplar® injection;Hectorol® injection
35 Vitamin D Status in Males in Jerusalem Area and Its Correlation to Parathyroid Hormone (PTH) Level and Bone Mineral Density Completed NCT01025128 Phase 4 25 OH vitamin D
36 Effect of Phosphate Binders on FGF-23 With Concurrent Calcitriol Completed NCT01748396 Phase 4 Calcitriol;Calcium Carbonate
37 Calcitriol in the Treatment of Immunoglobulin A (IgA) Nephropathy Completed NCT00319761 Phase 4 Calcitriol
38 Efficacy of Usual Vitamin D Supplementation and Its Impact on Children and Adolescents Calciuria. Completed NCT02238418 Phase 4 Cholecalciferol vial (100 000 UI)
39 Efficacy of Vitamin D2 to Treat Chronic Kidney Disease Mineral and Bone Disorder Completed NCT01633853 Phase 4 Vitamin D2;1,25(OH)2 Vit D3
40 Study of the Effect of Alendronate on Vascular Calcification and Arterial Stiffness in Chronic Kidney Disease Completed NCT00395382 Phase 4 Alendronate;Placebo
41 How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis Completed NCT00528788 Phase 4 doxercalciferol
42 ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis Completed NCT00379899 Phase 4 cinacalcet
43 A Study to Evaluate Alendronate Sodium /Vitamin D3 Combination Tablets(FOSAMAX PLUS) Versus Calcitriol in the Treatment of Osteoporosis in Postmenopausal Women in China (MK-0217A-264) Completed NCT01350934 Phase 4 alendronate 70-mg/vitamin D3 5600 IU combination tablet (Fosamax Plus);Calcitriol
44 Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients Recruiting NCT03182699 Phase 4
45 Efficacy and Safety of Cinacalcet in Ca, P and iPTH Levels in Patients With Mild, Moderate and Severe SHPT Recruiting NCT03123406 Phase 4 Cinacalcet HCl
46 Paricalcitol Improves Anemia of Inflammation Recruiting NCT02876211 Phase 4 Paricalcitol;Epoetin beta;Placebo
47 Cholecalciferol Supplementation in Restless Leg Syndrome in Patients With Chronic Kidney Disease Recruiting NCT03063190 Phase 4 Vitamin D;Placebo Oral Tablet
48 Intravenous Paricalcitol in Chronic Hemodialysis Patients Active, not recruiting NCT03023748 Phase 4 Intravenous Paricalcitol
49 The Efficacy of Niacin on Hyperphosphatemia in Patients Undergoing Haemodialysis Not yet recruiting NCT03163576 Phase 4 Niacin;Phosphate Binder
50 Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis Subjects Terminated NCT00664430 Phase 4 Calcitriol;Paricalcitol

Search NIH Clinical Center for Secondary Hyperparathyroidism of Renal Origin

Cochrane evidence based reviews: hyperparathyroidism, secondary

Genetic Tests for Secondary Hyperparathyroidism of Renal Origin

Anatomical Context for Secondary Hyperparathyroidism of Renal Origin

MalaCards organs/tissues related to Secondary Hyperparathyroidism of Renal Origin:

41
Kidney, Bone, Endothelial, Thyroid, Liver, Neutrophil, Lung

Publications for Secondary Hyperparathyroidism of Renal Origin

Articles related to Secondary Hyperparathyroidism of Renal Origin:

(show top 50) (show all 418)
# Title Authors Year
1
Calcitriol accelerates vascular calcification irrespective of vitamin K status in a rat model of CKD with hyperphosphatemia and secondary hyperparathyroidism. ( 29903718 )
2018
2
Cinacalcet versus Placebo for secondary hyperparathyroidism in chronic kidney disease patients: a meta-analysis of randomized controlled trials and trial sequential analysis. ( 29449603 )
2018
3
Treatment Based on Cinacalcet Reduces Oxidative Stress in Hemodialysis Patients with Secondary Hyperparathyroidism. ( 29879701 )
2018
4
Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes. ( 29423207 )
2018
5
Influence of Parathyroidectomy on Bone Metabolism and Bone Pain in Patients with Secondary Hyperparathyroidism. ( 29393259 )
2018
6
Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: a review on current data and place in therapy. ( 29910605 )
2018
7
Cholecalciferol Additively Reduces Serum Parathyroid Hormone Levels in Severe Secondary Hyperparathyroidism Treated with Calcitriol and Cinacalcet among Hemodialysis Patients. ( 29439405 )
2018
8
Periosteal chondroma of the cuboid with secondary aneurysmal bone cyst in a setting of secondary hyperparathyroidism. ( 29413778 )
2018
9
Case report: Electron microscopic evaluation of bone from a patient treated with cinacalcet hydrochloride, maxacalcitol, and alfacalcidol for hyperparathyroid bone disease with secondary hyperparathyroidism. ( 29492624 )
2018
10
Changes in bone mineral density after total parathyroidectomy without autotransplantation in the end-stage renal disease patients with secondary hyperparathyroidism. ( 29907149 )
2018
11
Dystrophic Calcifications in the Breast from Secondary Hyperparathyroidism. ( 29950967 )
2018
12
Unusually Large Brown tumor of Mandible in a Case of Secondary Hyperparathyroidism Mimicking Cherubism. ( 29643674 )
2018
13
Cortical and trabecular bone are equally affected in rats with renal failure and secondary hyperparathyroidism. ( 29394885 )
2018
14
Severe secondary hyperparathyroidism in patients on haemodialysis is associated with a high initial serum parathyroid hormone and beta-CrossLaps level: Results from an incident cohort. ( 29912988 )
2018
15
Ultrasound-based scores as predictors for nodular hyperplasia in patients with secondary hyperparathyroidism: a prospective validation study. ( 28054194 )
2017
16
Brown tumor: clinical findings of secondary hyperparathyroidism in patients with renal osteodystrophy. ( 28253186 )
2017
17
Pin1 and secondary hyperparathyroidism of chronic kidney disease: gene polymorphisms and protein levels. ( 27876426 )
2017
18
Evaluation of the different surgical parathyroidectomieson secondary hyperparathyroidism in uremia patients. ( 29205012 )
2017
19
Drug disposition model of radiolabeled etelcalcetide in patients with chronic kidney disease and secondary hyperparathyroidism on hemodialysis. ( 28063122 )
2017
20
Management of secondary hyperparathyroidism: practice patterns and outcomes of cinacalcet treatment with or without active vitaminA D in Austria and Switzerland - the observational TRANSIT Study. ( 28091752 )
2017
21
High Incidence of Secondary Hyperparathyroidism in Bariatric Patients: Comparing Different Procedures. ( 28921422 )
2017
22
Hyperparathyroidism caused by distant pulmonary lesions and parathyromatosis after ethanol injection/parathyroidectomy for secondary hyperparathyroidism. ( 28078796 )
2017
23
Management of secondary hyperparathyroidism: how and why? ( 28044233 )
2017
24
Pharmacokinetics of dexmedetomidine administered to patients with end-stage renal failure and secondary hyperparathyroidism undergoing general anaesthesia. ( 29247451 )
2017
25
A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients. ( 28057872 )
2017
26
Acute thyroiditis: An under-recognized complication of parathyroidectomy in end-stage renal failure patients with secondary hyperparathyroidism. ( 28621009 )
2017
27
<i>Let-7</i> and<i>MicroRNA-148</i>Regulate Parathyroid Hormone Levels in Secondary Hyperparathyroidism. ( 28298326 )
2017
28
Pharmacokinetics of a New Oral Vitamin D Receptor Activator (2-Methylene-19-Nor-(20S)-1I+,25-Dihydroxyvitamin D3) in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism on Hemodialysis. ( 28905271 )
2017
29
Risk factors and clinical course of hungry bone syndrome after total parathyroidectomy in dialysis patients with secondary hyperparathyroidism. ( 28073343 )
2017
30
Rates of secondary hyperparathyroidism after bypass operation for super-morbid obesity: An overlooked phenomenon. ( 27769660 )
2017
31
Cinacalcet versus Parathyroidectomy in the Treatment of Secondary Hyperparathyroidism Post Renal Transplantation. ( 27658167 )
2016
32
Long-term mortality after parathyroidectomy among chronic kidney disease patients with secondary hyperparathyroidism: a systematic review and meta-analysis. ( 27198474 )
2016
33
The relationship between total mass and blood supply of parathyroid glands and their secretion of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism. ( 26997379 )
2016
34
Literature review in the treatment of calciphylaxis: A case with uncontrolled and severe secondary hyperparathyroidism. ( 26958335 )
2016
35
Pharmacological Management of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease. ( 27142279 )
2016
36
Associations of the calcium-sensing receptor gene CASR rs7652589 SNP with nephrolithiasis and secondary hyperparathyroidism in haemodialysis patients. ( 27739473 )
2016
37
Down-regulation of ABCG2, a urate exporter, by parathyroid hormone enhances urate accumulation in secondary hyperparathyroidism. ( 27988213 )
2016
38
Population Pharmacokinetics and Pharmacodynamics of the Calcimimetic Etelcalcetide in Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis. ( 27639083 )
2016
39
Efficacy and safety of ultrasound-guided radiofrequency ablation of hyperplastic parathyroid gland for secondary hyperparathyroidism associated with chronic kidney disease. ( 28032671 )
2016
40
Brown tumor of secondary hyperparathyroidism: surgical approach and clinical outcome. ( 27640197 )
2016
41
Micro-RNAs in the parathyroid: a new portal in understanding secondary hyperparathyroidism. ( 27138227 )
2016
42
Warfarin skin necrosis mimicking calciphylaxis in a patient with secondary hyperparathyroidism undergoing peritoneal dialysis. ( 27069859 )
2016
43
Efficacy and safety of osteoporosis medications in a rat model of late-stage chronic kidney disease accompanied by secondary hyperparathyroidism and hyperphosphatemia. ( 27933339 )
2016
44
Surgical Attitude in Patients with Secondary Hyperparathyroidism Undergoing Dialysis. ( 26531784 )
2015
45
A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM). ( 25904755 )
2015
46
Effect of secondary hyperparathyroidism serum on endothelial cells and intervention with Klotho. ( 25873020 )
2015
47
Sagliker syndrome in patients with secondary hyperparathyroidism and chronic renal failure: Case report. ( 25661637 )
2015
48
Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism. ( 25873267 )
2015
49
Facial disfigurement due to osteitis fibrosa cystica or brown tumor from secondary hyperparathyroidism in patients on dialysis: A systematic review and an illustrative case report. ( 25828738 )
2015
50
Predicting postoperative total calcium requirements after parathyroidectomy in secondary hyperparathyroidism. ( 26552461 )
2015

Variations for Secondary Hyperparathyroidism of Renal Origin

Expression for Secondary Hyperparathyroidism of Renal Origin

Search GEO for disease gene expression data for Secondary Hyperparathyroidism of Renal Origin.

Pathways for Secondary Hyperparathyroidism of Renal Origin

GO Terms for Secondary Hyperparathyroidism of Renal Origin

Cellular components related to Secondary Hyperparathyroidism of Renal Origin according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.5 ALB BGLAP CALCA EPO FGF23 PTH
2 extracellular space GO:0005615 9.17 ALB BGLAP CALCA EPO FGF23 PTH

Biological processes related to Secondary Hyperparathyroidism of Renal Origin according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.88 CALCA EPO FGF23 PTH TNFRSF11B
2 response to lipopolysaccharide GO:0032496 9.8 ACP5 CYP27B1 EPO TNFRSF11B
3 cellular protein metabolic process GO:0044267 9.79 ALB CALCA FGF23
4 aging GO:0007568 9.79 BGLAP CALCA EPO
5 calcium ion transport GO:0006816 9.76 CASR CYP27B1 VDR
6 skeletal system development GO:0001501 9.73 BGLAP PTH TNFRSF11B VDR
7 cellular calcium ion homeostasis GO:0006874 9.67 CALCA CASR PTH VDR
8 embryo implantation GO:0007566 9.63 CALCA EPO
9 bone mineralization GO:0030282 9.63 BGLAP CYP27B1
10 response to testosterone GO:0033574 9.62 BGLAP EPO
11 decidualization GO:0046697 9.61 CYP27B1 VDR
12 bone resorption GO:0045453 9.6 ACP5 PTH
13 vasodilation GO:0042311 9.59 CALCA CASR
14 positive regulation of ossification GO:0045778 9.58 CALCA PTH
15 regulation of bone mineralization GO:0030500 9.58 BGLAP CYP27B1 FGF23
16 response to inorganic substance GO:0010035 9.57 BGLAP TNFRSF11B
17 positive regulation of keratinocyte differentiation GO:0045618 9.56 CYP27B1 VDR
18 negative regulation of bone resorption GO:0045779 9.55 CALCA TNFRSF11B
19 response to magnesium ion GO:0032026 9.54 FGF23 TNFRSF11B
20 response to fibroblast growth factor GO:0071774 9.52 CASR PTH
21 negative regulation of calcium ion transport into cytosol GO:0010523 9.51 CALCA EPO
22 response to vitamin D GO:0033280 9.5 BGLAP CYP27B1 PTH
23 vitamin D catabolic process GO:0042369 9.46 CYP27B1 FGF23
24 response to estrogen GO:0043627 9.46 BGLAP CYP27B1 EPO TNFRSF11B
25 vitamin D metabolic process GO:0042359 9.43 CYP27B1 FGF23 VDR
26 cellular response to vitamin D GO:0071305 9.13 BGLAP CASR FGF23
27 positive regulation of vitamin D 24-hydroxylase activity GO:0010980 8.8 CYP27B1 FGF23 VDR

Molecular functions related to Secondary Hyperparathyroidism of Renal Origin according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.8 CALCA EPO PTH

Sources for Secondary Hyperparathyroidism of Renal Origin

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....